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The Genetic Architecture of Diet-Induced 
Hepatic Fibrosis in Mice
Simon T. Hui,1 Zeyneb Kurt,2 Iina Tuominen,3 Frode Norheim,1 Richard C.Davis,1 Calvin Pan,1 Darwin L. Dirks,1 Clara E. Magyar,4 
Samuel W. French,4 Karthickeyan Chella Krishnan,1 Simon Sabir,1 Francisco Campos-Pérez,5 Nahum Méndez-Sánchez ,6  
Luis Macías-Kauffer,7 Paola León-Mimila,7 Samuel Canizales-Quinteros,7 Xia Yang,2 Simon W. Beaven,3 Adriana Huertas-Vazquez,1  
and Aldons J. Lusis1
We report the genetic analysis of a “humanized” hyperlipidemic mouse model for progressive nonalcoholic steato-
hepatitis (NASH) and fibrosis. Mice carrying transgenes for human apolipoprotein E*3-Leiden and cholesteryl ester 
transfer protein and fed a “Western” diet were studied on the genetic backgrounds of over 100 inbred mouse strains. 
The mice developed hepatic inf lammation and fibrosis that was highly dependent on genetic background, with vast 
differences in the degree of fibrosis. Histological analysis showed features characteristic of human NASH, including 
macrovesicular steatosis, hepatocellular ballooning, inf lammatory foci, and pericellular collagen deposition. Time 
course experiments indicated that while hepatic triglyceride levels increased steadily on the diet, hepatic fibrosis 
occurred at about 12 weeks. We found that the genetic variation predisposing to NASH and fibrosis differs mark-
edly from that predisposing to simple steatosis, consistent with a multistep model in which distinct genetic factors 
are involved. Moreover, genome-wide association identified distinct genetic loci contributing to steatosis and NASH. 
Finally, we used hepatic expression data from the mouse panel and from 68 bariatric surgery patients with normal 
liver, steatosis, or NASH to identify enriched biological pathways. Conclusion: The pathways showed substantial 
overlap between our mouse model and the human disease.  (Hepatology 2018;68:2182-2196).
Abbreviations: ALT, alanine aminotransferase; APOE*3, apolipoprotein E*3; CETP, cholesteryl ester transfer protein; DAVID, Database for 
Annotation, Visualization and Integrated Discovery; ECM, extracellular matrix; ELISA, enzyme-linked immunosorbent assay; eQTL, expression 
quantitative trait locus; Fuca1, alpha-L-fucosidase 1; FDR, false discovery rate; GWAS, genome-wide association study; HMDP, Hybrid Mouse 
Diversity Panel; HOMA-IR, homeostasis model assessment of insulin resistance; LD, linkage disequilibrium; LDL, low-density lipoprotein; 
MCP-1, monocyte chemoattractant protein 1; MSEA, marker set enrichment analysis; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic 
steatohepatitis; Phactr, phosphatase and actin regulator 2; RNA-seq, RNA-sequencing; SNP, single-nucleotide polymorphism; TG, triglycerides.
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SEE EDITORIAL ON PAGE 2059
Nonalcoholic fatty liver disease (NAFLD) is a multistage disease comprised of a spec-trum of abnormalities ranging from simple 
steatosis to nonalcoholic steatohepatitis (NASH), 
characterized by inf lammation and liver cell dam-
age. With sustained liver injury, individuals with 
NASH are at risk of developing progressive fibro-
sis, cirrhosis, and hepatocellular carcinoma.(1,2) 
While simple steatosis appears to be benign in 
most cases, NASH is associated with increased 
overall morbidity and mortality.(2) The etiology of 
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this disease is complex, involving multiple genetic 
and environmental factors and substantial overlap 
with obesity.(3) Human genome-wide association 
studies (GWAS) have identified several loci and 
candidate genes for NAFLD, but these account for 
a small proportion of disease heritability.(4) Among 
them, patatin-like phospholipase domain-contain-
ing 3 (PNPLA3) and transmembrane 6 superfamily 
member 2 (TM6SF2) have been validated in mul-
tiple studies.(5)
When fed a high-fat, high-sucrose diet, mice typi-
cally develop steatosis but do not progress to NASH.(6) 
We now report that mice with a “humanized” lipo-
protein profile due to transgenic expression of human 
apolipoprotein (APO) E*3-Leiden and human cho-
lesteryl ester transfer protein (CETP) exhibit the 
entire spectrum of NAFLD when fed a “Western” 
diet. To understand the pathways underlying NASH/
fibrosis, we introduced the transgenes onto a panel 
of over 100 different inbred strains of mice known 
as the Hybrid Mouse Diversity Panel (HMDP). We 
observed that the degree of fibrosis across the strains 
varied more than 500-fold, indicating a strong genetic 
component. We examined a number of molecular 
phenotypes across the strains, including global gene 
expression in liver, cytokine levels in plasma, and a 
number of relevant plasma metabolites. A time course 
study revealed key features of NASH progression. 
Our results indicate that the genetic factors contrib-
uting to steatosis and to NASH are largely distinct, 
in accordance with a two-step model. Finally, using 
genetic and RNA-sequencing (RNA-seq) analysis of 
human liver biopsies, we provide evidence that many 
of the same pathways are shared by our mouse model 
and by humans.
Materials and Methods
aNiMalS
Transgenic mice expressing human CETP were 
obtained from The Jackson Laboratory, and mice 
carrying the human APOE*3-Leiden variant were 
kindly provided by Dr. L. Havekes.(7,8) These mice 
were interbred to create a strain carrying both trans-
genes in a C57BL/6J background and subsequently 
bred to females from about 100 common inbred 
strains (Supporting Table S1). Animals were main-
tained on a 12-hour light–dark cycle with ad libitum 
access to water. Male mice (8-10 weeks old) were fed a 
“Western” diet (33 kcal% fat from cocoa butter and 1% 
cholesterol; Research Diets; catalog no. D10042101) 
for 16 weeks. Body composition was measured by 
nuclear magnetic resonance (Brüker Biospin Corp., 
Billerica, MA). At the end of the study, mice were 
fasted for 4 hours beginning at 6:00 am and sacrificed 
at 10:00 am. To avoid sampling error, liver samples for 
histological and microarray analyses were taken from 
the same lobe in each mouse. All animal work was 
approved by the University of California, Los Angeles, 
Animal Research Committee, the institutional animal 
care and use committee.
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QuaNtitatiVe aSSeSSMeNt oF 
SteatoSiS aND FiBRoSiS iN tHe 
liVeR
Liver lipids were quantitated by methods accord-
ing to Hui et al.(6) For histological examination, livers 
were fixed in 10% formalin, embedded in paraffin, sec-
tioned at 5 µm, and stained with picrosirius red. Slides 
were scanned at ×20 magnification (Aperio ScanScope 
XT; Leica Biosystems). Liver fibrosis was measured as 
a quantitative trait from liver sections using picrosirius 
red staining followed by a whole-slide digital imaging 
algorithm to quantify the fibrosis in each section as 
a percentage of the total liver area. The trained algo-
rithm can correctly identify pathologic fibrosis and 
differentiate it from collagen staining of the vascu-
lar wall and liver capsule, which is excluded from the 
quantitation (Supporting Information and Fig. S1). 
This method was validated by showing that the fibro-
sed area correlated with both hepatic hydroxypro-
line content (r = 0.54, P = 6.1 × 10–7) and blinded 
fibrosis score assessed by a liver pathologist (r = 0.80, 
P = 8.4 × 10–18) (Supporting Fig. S2).
plaSMa lipiDS, eNZyMeS, 
CytoKiNeS, aND MetaBoliteS
Plasma lipid profiles and alanine aminotransferase 
(ALT) activity were measured by colorimetric analysis 
as described.(6) Quantification of plasma cytokines was 
carried out in a custom multiplexed cytokine enzyme-
linked immunosorbent assay (ELISA) kit using an 
electrochemiluminescent detection method per the 
manufacturer’s instructions (Meso Scale Discovery, 
Rockville, MD). Plasma insulin was measured using 
the mouse insulin ELISA kit (80-INSMS-E01) from 
Alpco (Salem, NH).(8) Plasma metabolites in a subset 
of 124 mice from 52 strains (Supporting Table S2) 
were quantified using time-of-flight tandem mass 
spectrometry as described.(9)
RNa iSolatioN aND geNe 
eXpReSSioN aNalySiS
Liver RNA was isolated from a subset of 249 liv-
ers from 102 strains (Supporting Table S3) and ana-
lyzed for global gene expression using Affymetrix 
HT-MG_430 PM Microarrays as described.(10) 
Expression quantitative trait loci (eQTL) in liver were 
mapped using the FaST-LMM algorithm with cor-
rection for population structure.(11) Correlations were 
calculated using the bicor function from the WGCNA 
R package.(12) Gene Ontology (GO) enrichment 
analysis was performed using the Database for 
Annotation, Visualization and Integrated Discovery 
(DAVID, v6.7) program.(13)
geNoMe-WiDe aSSoCiatioN 
aNalySiS
High-density genotypes for inbred strains of mice 
were generated by the Mouse Diversity Array.(14) 
Genome-wide association mapping of hepatic fibrosis 
was performed using FaST-LMM.(8) Deleterious mis-
sense mutations were identified using the PROVEAN 
prediction algorithm.(15)
RNa-SeQ oF HuMaN NaFlD 
liVeR BiopSieS
A total of 68 male and female nonrelated Mexican 
mestizo subjects who underwent bariatric surgery 
for morbid obesity with a body mass index (BMI) 
≥40 kg/m2 were included in the study. The mean 
age was 39.1 ± 9.4 years. Detailed characteristics of 
the study have been reported.(16) Anthropometric 
and biochemical parameters of the study popula-
tion can be found in Supporting Table S4. Liver 
biopsies were collected in RNAlater (Sigma, St. 
Louis, MO) and stored at –80°C. Genotyping was 
performed using the Multi-Ethnic Genotyping 
Array (Illumina, San Diego, CA). RNA quality was 
assessed using the Bioanalyzer RNA chip analysis 
to ensure that the RNA integrity number was >7. 
Complementary DNA libraries were prepared using 
the TruSeq RNA Stranded Total RNA Library 
Preparation kit (Illumina) and sequenced using an 
Illumina HiSeq2500 instrument, generating approx-
imately 50 million reads/sample. After data quality 
control, sequencing reads were mapped to the human 
reference genome using TopHat and quantified using 
Cufflinks. This study was approved by the institu-
tional review boards of the National Institute of 
Genomic Medicine (Mexico) and the Hospital Dr. 
General Ruben Leñero. All participants provided 
written informed consent prior to their inclusion. 
The study was performed according to the principles 
of the Declaration of Helsinki.
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CoMpaRiSoN oF BiologiCal 
patHWayS aSSoCiateD WitH 
NaSH BetWeeN MiCe aND 
HuMaNS
Marker set enrichment analysis (MSEA) was 
employed to identify causal biological pathways of 
NASH/fibrosis in our mouse model and a human 
bariatric surgery cohort.(17,18) Genes in each canoni-
cal pathway or coexpression module were mapped to 
single-nucleotide polymorphisms (SNPs) using liver 
eQTLs and then integrated with GWAS of mouse 
liver fibrosis or human NASH to capture strong, mod-
erate, and subtle genetic signals. Genotyping of the 
obese patients was performed using the Multi-Ethnic 
Genotyping Array. A total of 507,122 SNPs remained 
after removal of SNPs with a minor allele frequency 
<5% and Hardy-Weinberg equilibrium P < 1 × 10–5. 
Additional SNP imputation with Beagle resulted in 
865,847 SNPs analyzed.(19) Genotypic associations 
for NASH were estimated in a mixed linear model 
with, sex, age, and BMI as fixed effects and the genetic 
relatedness matrix as a random effect. Liver tissue 
eQTLs in humans were calculated using the FaST-
LMM algorithm.(11) Additional human liver tissue 
eQTLs collected from multiple resources including 
Massachusetts General Hospital(20) and the Genotype-
Tissue Expression project(21) were pooled together and 
used in the MSEA. Cis-eQTLs (or “local” eQTLs) 
were defined as those within 1 Mb of the gene. In total 
315,652 liver tissue cis-eQTL associations (false discov-
ery rate [FDR] < 0.05) were included in the analysis. 
Pathways were considered to be shared between mice 
and humans if >50% of genes were shared. Associations 
between SNPs affecting expression of genes in a path-
way were tested for association with NASH/fibrosis, 
and the set of P values was compared with random 
genes. An FDR < 0.05 cutoff was used.
Additional details about the methodology are pro-
vided in Supporting Information.
Results
a “HuMaNiZeD” HypeRlipiDeMia 
MouSe MoDel FoR pRogReSSiVe 
NaSH aND FiBRoSiS
Mice transgenic for APOE*3-Leiden and CETP 
and fed a high-fat, high-cholesterol diet are a model 
of metabolic syndrome and atherosclerosis.(22,23) 
During a study of atherosclerosis,(8) we observed that 
transgenic mice on a pure C57BL/6J background 
develop features characteristic of steatosis, NASH, 
and fibrosis. Unlike mice fed with the commonly used 
methionine/choline-deficient diet to induce fibrosis, 
the CETP and APOE*3-Leiden transgenic mice fed 
a Western diet containing 1% cholesterol developed 
insulin resistance along with a steady increase in body 
weight, adiposity, and insulin resistance (Supporting 
Fig. S3A-C). Liver triglycerides (TG) accumulated 
progressively, reaching a plateau of ~6-fold at 12 weeks 
(Fig. 1,3A). Hepatic cholesterol levels began increas-
ing within 2 weeks of the beginning of diet feeding 
(Fig. 1B), while unesterified cholesterol did not show 
a sharp increase until week 8 (Fig. 1C). Hepatic phos-
pholipid levels were not altered (data not shown). 
Histological analysis showed that steatosis and hepa-
tocellular ballooning were apparent at 8 weeks (Fig. 
1D). Subsequently, advanced steatosis developed, 
as evidenced by the presence of macrovesicular ste-
atosis (Fig. 1D). Collagen deposition was observed 
around week 12, and overt hepatic fibrosis developed 
between weeks 12 and 16 (Fig. 1E). The severity of 
histological changes paralleled the increasing levels of 
proinflammatory cytokines (including tumor necro-
sis factor alpha [TNF-α], interleukin 6 [IL-6], and 
monocyte chemoattractant protein 1 [MCP-1]) in 
the plasma (Fig. 2A-C), a characteristic of NASH 
patients. Furthermore, these changes were accompa-
nied by progressive increases in the expression of gene 
markers for immune cell infiltration (F4/80, MCP-1; 
Fig. 2D,E) and fibrogenesis (collagen type 1 alpha 1 
[Col1a1]; Fig. 2F).
iNDepeNDeNt geNetiC 
RegulatioN oF HepatiC 
SteatoSiS aND FiBRoSiS
To assess the impact of genetic variation on NASH 
susceptibility, each HMDP strain was crossed to 
a C57BL/6J male mouse hemizygous for human 
APOE*3-Leiden and homozygous for CETP trans-
genes. F1 progeny hemizygous for both APOE*3-
Leiden and CETP transgenes were selected and fed 
a “Western” high-fat, high-cholesterol diet for 16 
weeks.(8) Overall, 619 male mice from 102 strains 
were surveyed (Supporting Table S1). A wide spec-
trum of fibrosis, predominantly pericellular fibrosis, 
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was observed among the strains (Fig. 3A). Female 
mice generally showed a similar strain distribution 
for fibrosis, although there was evidence of sexual 
dimorphism as well (Supporting Fig. S4). While some 
strains are resistant to fibrosis (Fig. 3B), livers from 
susceptible strains displayed signature histological fea-
tures of human NASH livers, including macrovascular 
steatosis, inflammatory foci, hepatocellular ballooning, 
and a pericellular (“chicken wire”) pattern of collagen 
deposition (Fig. 3C,D). The degree of fibrosis was 
Fig. 1. Change in hepatic histology and lipid levels during progression of NASH. Male C57BL/6J mice carrying human APOE*3-
Leiden and CETP transgenes were fed a “Western” high-fat, high-cholesterol diet for 0-16 weeks. Hepatic levels of TG (A), total 
cholesterol (B), and unesterified cholesterol (C) are presented as mean ± SEM from 4-10 mice per group. Control mice were fed 16 
weeks on chow. (D) Liver sections were stained for collagen with picrosirius red at the indicated time after diet, and the fibrosis score 
was determined by a pathologist blinded to the study (E). Abbreviations: TC, total cholesterol; UC, unesterified cholesterol.
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positively correlated with liver injury, as shown by sig-
nificant correlation between hepatic fibrosis and ALT 
activity in the plasma (Fig. 3E).
We previously studied the HMDP inbred mouse 
strains on a high-fat, high-sucrose diet, which results 
in dramatic steatosis but little or no fibrosis.(6) We 
examined whether the same genetic background 
would confer susceptibility equally to steatosis and 
fibrosis. No significant correlation was observed 
between the strain susceptibility to steatosis in the 
previous cohort and that to NASH/fibrosis in the 
present study (Fig. 3F), indicating that these two pro-
cesses were regulated largely by independent genetic 
determinants.
Fig. 2. Change in plasma cytokines and hepatic gene expression during progression of NASH. Male C57BL/6J mice carrying human 
APOE*3-Leiden and CETP transgenes were fed a “Western” diet for 0-16 weeks. Control mice were fed for 16 weeks on chow. Plasma 
levels (picograms per milliliter) of TNF-α (A), IL-6 (B), and MCP-1 (C) were measured by ELISA. Data are mean ± SEM from 
three mice per group. Liver expression of F4/80 (D), MCP-1 (E), and Col1a1 (F) was measured by quantitative PCR and normalized 
to ribosomal protein L4. Fold change was compared to the 0 week diet group. Data are presented as mean ± SEM from 4-10 mice per 
group.
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aSSoCiatioN oF HepatiC 
CHoleSteRol leVelS WitH 
HepatiC FiBRoSiS
Among the HMDP of F1 transgenic mice, signifi-
cant correlations between hepatic fibrosis and hepatic 
total (r = 0.26) and unesterified (r = 0.23) cholesterol 
levels (Fig. 4A; Supporting Table S5) were observed. 
The onset of fibrosis coincided with a sharp increase 
in intracellular unesterified cholesterol (Fig. 1C,D), 
in accordance with previous studies showing that free 
cholesterol accumulation in stellate cells promotes 
transforming growth factor beta (TGFβ) activa-
tion and hepatic fibrosis.(24) In contrast, hepatic TG 
Fig. 3. Effects of genetic background on hepatic fibrosis. (A) Quantitation of hepatic fibrosis among 101 male mice (mean + SEM). 
Data from C57BL/6J mice are highlighted in dark blue. (B-D) Liver sections were stained with picrosirius red. Representative slides 
showing liver histology from a resistant strain (AXB12/PgnJ, B) and a susceptible strain (BXD19/TyJ, C). Characteristic histological 
features typically seen in human NASH exhibited by BXD19/TyJ mice are indicated in (D) at a higher magnification. (E) Correlation 
between hepatic fibrosis and plasma ALT activity in male mice. (F) Correlation between hepatic fibrosis in mice of the current study 
and hepatic steatosis in mice fed a high-fat/high-sucrose diet.(6) Each data point represents strain average values for fibrosis and hepatic 
TG levels. r indicates biweight midcorrelation. Abbreviations: Ath, atherosclerosis; Ob, obese.
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(r = –0.35) and phospholipid (r = –0.22) levels were 
negatively correlated with fibrosis at later stages, the 
latter perhaps reflecting larger lipid droplets as mac-
rovesicular steatosis. As in human NASH, hepatic 
fibrosis was associated with hyperlipidemia, including 
significant correlations with plasma TG (r = 0.42), 
free fatty acids (r = 0.20), total cholesterol (r = 0.42), 
unesterified cholesterol (r = 0.55), and very low- 
density lipoprotein + low-density lipoprotein (LDL) 
cholesterol (r = 0.36) (Fig. 4A; Supporting Table S5). 
While the homeostasis model assessment of insulin 
resistance (HOMA-IR) was positively correlated with 
body weight, fat mass, and insulin levels, it showed 
only a modest correlation with hepatic fibrosis, in 
contrast to the strong correlation with steatosis in 
mice fed a high-fat, high-sucrose diet.(6) We did not 
observe significant correlations between fibrosis and 
body weight, gonadal fat mass, or atherosclerotic 
lesions (Fig. 4A).
alteReD aMiNo aCiD aND 
Fatty aCiD MetaBoliSM iN 
HepatiC FiBRoSiS
Previous metabolomics studies have identified 
amino acid abnormalities associated with NAFLD in 
humans.(25) Therefore, we performed targeted metab-
olomic analysis of polar metabolites in the plasma of 
a subset of our mice (Fig 4B; Supporting Table S6). 
Among the metabolites measured, plasma arginine 
exhibited the strongest correlation with hepatic fibro-
sis (r = –0.38). On the other hand, plasma levels of 
choline (r = 0.34), betaine (r = 0.19), and short chain 
acyl-carnitines were positively correlated with hepatic 
fibrosis.
gloBal tRaNSCRiptoMiC 
pRoFiliNg ReVealS DiStiNCt 
patHWayS uNDeRlyiNg 
SteatoSiS aND FiBRoSiS
To gain insights into the fibrotic process, we quan-
titated global gene expression in the livers across all 
102 strains by microarrays (Supporting Table S3). The 
top 1,000 genes correlated with hepatic fibrosis 
(P < 1.3 × 10–9) were analyzed using DAVID to test 
for enrichment of GO categories (Fig. 5A). We found 
10 enriched pathways which are broadly related to 
(1) collagen metabolism (collagen fibril organization, 
extracellular matrix [ECM] structural constituent, 
ECM–receptor interaction, focal adhesion, and pro-
tein digestion and absorption), (2) stellate cell activa-
tion (platelet-derived growth factor binding), (3) lipid 
metabolism (fatty acid metabolic process, oxidation- 
reduction process), (4) flavonoid metabolism, and (5) 
insulin signaling (phosphoinositide 3-kinase–Akt sig-
naling pathway). Most of these pathways are consistent 
with pathways known to be important in maintaining 
hepatic lipid balance and response to hepatic injury.
We also examined how individual gene expression 
varied with fibrosis-related clinical traits (LDL cho-
lesterol, plasma arginine, hepatic TG, adiposity, and 
HOMA-IR) (Fig. 5B). Unsupervised hierarchical 
clustering showed that there was parallel expression 
between many of the genes correlated with hepatic 
fibrosis and LDL cholesterol (Fig. 5B, clusters 1-3). 
In contrast, the expression pattern of genes associated 
with plasma arginine and, to a lesser extent, hepatic 
TG showed a reciprocal pattern compared to fibrosis 
(Fig. 5B, clusters 1-3). Genes correlated with adiposity 
and HOMA-IR showed only weak correlation with 
hepatic fibrosis. This is in sharp contrast to the gene 
expression pattern in the high-fat/high-sucrose diet–
induced steatosis model,(6) in which genes associated 
with adiposity and HOMA-IR paralleled those asso-
ciated with hepatic steatosis (Fig. 5C, clusters 4-6). 
The distinct gene expression signatures associated 
with hepatic steatosis and fibrosis suggest that the 
genetic regulation of these two stages of NAFLD is 
different.
iDeNtiFiCatioN oF FiBRoSiS 
CaNDiDate geNeS By gWaS
To identify genetic loci contributing to hepatic 
fibrosis, we performed genome-wide association 
Fig. 4. Correlation of fibrosis with clinical traits and plasma metabolites. Results are represented as heatmaps. Correlations of liver 
fibrosis and TG with clinical traits and atherosclerotic lesion area are shown in (A), and correlations between fibrosis and plasma 
metabolites are shown in (B). Abbreviations: ADMA, asymmetric dimethylarginine; bicor, biweight midcorrelation; GABR, global 
arginine bioavailability ratio; HDL, high-density lipoprotein cholesterol; MMA, N-mono-methylarginine; SDMA, symmetric 
dimethylarginine; TMAO, trimethylamine N-oxide.
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analyses. The threshold for genome-wide signifi-
cance was based on simulation and permutation, as 
described.(26) Two genome-wide significant loci for 
hepatic fibrosis were identified in male mice (Fig. 6A) 
on chromosomes 10 and 15. The peak SNP 
(rs50309490, P = 1.2 × 10–6) for the chromosome 
10 locus falls within a linkage disequilibrium (LD) 
block ~2.6 Mb containing 16 genes (Fig. 6B). To 
Fig. 5. Transcriptomic analysis of liver gene expression. (A) Enrichment pathways from top 1,000 genes correlated with hepatic 
fibrosis identified by DAVID. Benjamini-corrected P values are shown as –log (p) on the x-axis. (B,C) Full-length view of the cluster 
diagram with individual gene probes along the vertical axis and selected clinical traits along the horizontal axis. Positive correlations 
between transcript level and clinical trait are indicated in red and negative correlations in blue. Results from CETP and APOE*3-
Leiden mice on a high-fat, high-cholesterol diet for 16 weeks are shown in (B), and results from HMDP mice fed a high-fat, high-
sucrose diet for 8 weeks are shown in (C). Abbreviations: bicor, biweight midcorrelation; PI3K, phosphoinositide 3-kinase.
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prioritize candidate genes in this locus, we identified 
genes whose expression was controlled locally or that 
exhibited missense mutations leading to predicted 
deleterious effects. Significant local or cis-eQTLs are 
present in alpha-L-fucosidase 1 (Fuca1; rs29329055, 
P = 4.9 × 10–6) and phosphatase and actin regulator 
2 (Phactr2; rs50482796, P = 1.0 × 10–11). In addition, 
Phactr2 has a potential deleterious missense mutation 
(S217Y) (Supporting Table S7). The peak SNP of the 
chromosome 15 locus (rs31853140, P = 1.5 × 10–6) is 
within an LD block of ~1.6 Mb, containing seven can-
didate genes (Fig. 6C). Eukaryotic translation initia-
tion factor 3 subunit H (Eif3h) is the only gene whose 
expression correlated with liver fibrosis and exhibits a 
cis-eQTL (rs38654821, P = 1.3 × 10–6). Association 
mapping for hepatic TG yielded a completely different 
associated pattern compared to fibrosis (Fig. 6D). The 
peak SNP (rs29935539, P = 4.4 × 10–7) lies within an 
Fig. 6. Genome-wide association mapping of hepatic fibrosis and steatosis. (A) Manhattan plot showing the association of SNP 
genotype with hepatic fibrosis (A) and hepatic TG (D). Red line represents the threshold for genome-wide significance. LocusZoom 
plots are shown for genome-wide significant loci on chromosome 10 (B), chromosome 15 (C), and chromosome 6 (E). Association P 
values for steatosis and hepatic fibrosis for the peak SNPs in genome-wide significant loci for hepatic fibrosis or steatosis are shown in 
(F). Abbreviation: HF/HS, high-fat, high-sucrose.
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LD block of ~1 Mb on chromosome 6 and contains 
only four genes (Fig. 6E). Previously, we identified a 
locus on chromosome 7 for steatosis using HMDP 
strains on a high-fat/high-sucrose diet.(6) The distri-
bution of steatosis susceptibility across the HMDP 
in that model was only modestly correlated with the 
fibrosis reported here (Fig. 3F), and the GWAS loci 
for steatosis and fibrosis differed (Fig. 6F). These data 
suggest that the genetic factors affecting susceptibility 
to the two traits differ.
MouSe aND HuMaN NaSH/
FiBRoSiS patHWayS eXHiBit 
SuBStaNtial oVeRlap
To evaluate the relevance of our mouse model to 
that of human pathophysiology, we examined the 
transcriptomic context of our mouse model in rela-
tion to human NAFLD. Significant correlations were 
found between liver fibrosis and genes implicated 
in human GWAS for NAFLD, suggesting that the 
hepatic transcriptomic context in our mice resem-
bles that in human NASH (Table 1). We further 
compared our mouse results to data from 68 bariat-
ric surgery patients exhibiting a range of NAFLD 
phenotypes based on histological assessment using 
liver biopsies. The human liver biopsies were also 
subjected to RNA-seq analysis to allow modeling 
biologic networks. We identified pathways associ-
ated with NASH/fibrosis in both species using the 
MSEA pipeline as described under Materials and 
Methods. Briefly, this method tests for overrepresen-
tation of disease-related GWAS signals among the 
eQTLs mapped to individual pathways compared to 
random sets of genes.(17) At an FDR of <5%, 60% of 
the mouse fibrosis causal mechanisms were identified 
in causal human NASH subnetworks (Fig. 7). Nine 
pathways were found to be shared between mouse and 
human livers: innate and adaptive immune system, cell 
cycle, notch signaling, TGFβ signaling, Wnt signal-
ing, signal transduction, neurotrophin signaling, per-
oxisome proliferator– activated receptor signaling and 
peroxisome metabolism, and viral human immuno-
deficiency virus infection. Six gene sets were mouse- 
specific (fatty acid, triacylglycerol, and ketone body 
metabolism, mitogen-activated protein kinase signal-
ing, mRNA processing, and transcription pathways), 
whereas 12 gene sets were human-specific (cytokine 
signaling, chemokine receptors, ECM and matrisome 
terms, hedgehog and Janus kinase–signal transducer 
and activator of transcription signaling, apoptosis, 
adherens junctions, circadian clock terms) (Fig. 7).
Discussion
We report a systems genetics analysis of NASH/
fibrosis using hyperlipidemic human CETP and 
APOE*3-Leiden transgenic mice that develop many 
features and molecular signatures characteristic of 
human NASH pathophysiology. Several conclusions 
have emerged. First, we demonstrate that hepatic 
fibrosis in mice is strongly dependent on genetic 
background, consistent with heritability estimates in 
humans.(3) Second, our studies indicate that hepatic 
steatosis and NASH/fibrosis are mediated by dis-
tinct genetic factors, consistent with a multistep 
model of NAFLD. Third, our multi-omics analysis 
taBle 1. Correlation Between expression of Human gWaS Candidate genes for NaFlD/NaSH and  
liver Fibrosis in Mice
Gene Name r P
Ppp1r3b Protein phosphatase 1, regulatory (inhibitor) subunit 3B –0.251 0.011
Tm6sf2 Transmembrane 6 superfamily member 2 –0.087 0.384
Gckr Glucokinase regulatory protein –0.220 0.026
Col13a1 Collagen, type XIII, alpha 1 –0.359 2.0E-04
Pnpla3 Patatin-like phospholipase domain containing 3 –0.177 0.076
Pzp Pregnancy zone protein 0.112 0.261
Mboat7 Membrane bound O-acyltransferase domain containing 7 –0.405 2.5E-05
Lyplal1 Lysophospholipase-like 1 –0.233 0.018
Fdft1 Farnesyl diphosphate farnesyl transferase 1 –0.238 0.016
Trib1 Tribbles homolog 1 (Drosophila) –0.208 0.036
Ncan Neurocan –0.251 0.011
Hui et al. Hepatology, December 2018
2194
of transcripts and metabolites has identified pathways 
and markers associated with NASH/fibrosis. Finally, 
we have performed a preliminary comparison of path-
ways underlying NASH and fibrosis in our mouse 
model compared to humans, observing very substan-
tial overlap.
Due to the transgenic expression of CETP, these 
mice exhibit a high-density lipoprotein:LDL lipopro-
tein profile resembling that of humans, although both 
apoB48 and apoB100 are present in LDL, whereas 
human LDL only contains ApoB100. The contri-
bution of apoB48-containing lipoprotein to NASH 
remains to be studied. Nevertheless, our results indi-
cate that hyperlipidemic transgenic mice expressing 
human CETP and APOE*3-Leiden provide a use-
ful model for NASH research. First, unlike the com-
monly used methionine/choline-deficient diet model, 
which has a drawback of inducing rapid weight loss 
and decreasing adiposity without insulin resistance, 
our model showed weight gain and insulin resistance. 
Second, histological analysis showed that our mice 
developed the pathological characteristics of human 
NASH: macrovascular steatosis, hepatocyte balloon-
ing, inflammatory foci, and pericellular patterns of 
collagen deposition. Third, at the molecular level, 
markers for inflammation, apoptosis, and fibrosis were 
strongly correlated with fibrosis in our mice. Fourth, 
transcriptomic analysis showed that there was sig-
nificant overlap between pathways associated with 
fibrosis in both mice and a cohort of bariatric sur-
gery patients exhibiting NASH. During the course 
of these studies, others reported a similar finding 
with APOE*3-Leiden, CETP transgenic mice on a 
C57BL/6J background.(22,27)
While we are underpowered to detect interstrain 
differences due to low replicate numbers, associa-
tion and correlation analyses were done with the 
entire population of mice consisting of >100 strains 
and were not dependent on strain differences, allow-
ing sufficient statistical power to detect difference in 
genetic pathways. Association mapping was done after 
correction of population structure, and genome-wide 
significant loci were identified. Association mapping 
using data from 102 strains of F1 HMDP transgenic 
mice identified two loci for liver fibrosis, and we pri-
oritized candidate genes in the loci using transcrip-
tomic and protein coding data. At the chromosome 10 
locus, we identified two genes (Phactr2 and Fuca1) as 
Fig. 7. Comparison between causal pathways associated with human NASH and mouse liver fibrosis. Pathways were identified using 
the MSEA algorithm.(17,18) Abbreviations: BCR, B-cell receptor; HIV, human immunodeficiency virus; MAPK, mitogen-activated 
protein kinase; PPAR, peroxisome proliferator-activated receptor; TGF, transforming growth factor.
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strong candidates. Phactr2 belongs to member of the 
largely uncharacterized PHACTR family of protein 
phosphatase 1–binding and actin-binding proteins 
involved in inflammation and cell cycle control.(28,29) 
Fuca1 encodes the lysosomal hydrolase α-L-fuco-
sidase implicated in cell growth and signaling.(30) 
At the chromosome 15 locus, Eif3h, encoding the 
eukaryotic translation initiation factor, is a candidate 
that is involved in the cell cycle.(31) One limitation 
of our study is that all F1 mice carry one chromo-
some from C57BL/6J and one chromosome from the 
HMDP. Thus, recessive risk alleles not present in the 
C57BL/6J genome will not be detected and mapped 
under our mouse model. This is unlikely to be a major 
issue, however, because the vast majority of common 
variations exhibit additive inheritance.(32)
To help identify markers for NAFLD and to better 
understand the underlying pathways, we performed 
metabolomic and transcriptomic analyses. Arginine 
was strongly negatively correlated with fibrosis, while 
choline, betaine, and acyl-carnitines were significantly 
positively correlated. Arginine serves as a precur-
sor not only in protein synthesis and the urea cycle 
but also in the generation of polyamines, creatine, 
and nitric oxide. Treatment with arginine appears 
to block oxidative stress–induced NASH by inhib-
iting cytochrome P450 2E1 activity, decreasing the 
TNF-α level and restoring activities of endothelial 
nitric oxide synthase and antioxidant enzymes as well 
as glutathione levels.(33) Previous studies have shown 
that treatment with betaine improved nonalcoholic 
fatty liver and associated hepatic insulin resistance 
in mice.(34) Short-chain (C2, C3, C4, and C5) acyl 
derivatives of carnitine were positively correlated with 
fibrosis, whereas the precursor of carnitine, butyro-
betaine, was inversely correlated. Elevated levels of 
acyl-carnitine are indicative of incomplete oxidation 
of fatty acids in the mitochondria, consistent with 
the notion that impaired fatty acid oxidation con-
tributes to lipid accumulation and reactive oxygen 
species generation in the liver. In addition, elevated 
short-chain acylcarnitine levels may be contributed by 
altered branched-chain amino acid metabolism in the 
skeletal muscle.(35)
We compared our global mouse transcriptomic 
data with those from livers from a cohort of bariatric 
surgery patients selected for a broad range of NAFLD 
phenotypes, enabling testing for enrichment of canon-
ical pathways and comparison of pathways associated 
with NAFLD phenotypes in mice and humans. The 
results were consistent with the GWAS findings indi-
cating independent pathways contributing to steato-
sis and to NASH/fibrosis. While the mouse–human 
comparison must be considered preliminary, given 
the relatively small number of individuals examined, 
the pathway overlap was highly significant (Fig. 7). 
Supporting this conclusion, the hepatic expression 
of several human GWAS candidate genes, including 
PNPLA3, was correlated with fibrosis in our mouse 
model (Table 1). These results are in contrast to a 
recent study that compared gene expression in human 
NAFLD livers with nine mouse steatosis models.(36) 
The failure to observe significant overlap in that study 
may have been due in part to the fact that the mouse 
samples were obtained from a single time point with-
out histological staging, whereas our study compared 
a range of NASH/fibrosis phenotypes in both the 
mouse and human samples.
Our comprehensive multi-omic data should serve 
as a rich resource for future studies of NASH and 
fibrosis. Primary data are available from the authors.
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